You are here

INVOKAMET® XR and INVOKAMET® (canagliflozin/metformin HCl) offer your patients tailored therapy and the potential to reduce pill burden

Available as once-daily and twice-daily dosing options1,2

INVOKAMET® XR is available in 4 strengths1



The dosage of INVOKAMET® XR and INVOKAMET® should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose of canagliflozin (300 mg) and metformin (2000 mg).1,2

Individualize the starting dose of INVOKAMET® XR based on the effectiveness and tolerability of the patient's current regimen1

In patients currently not treated with either INVOKANA® or metformin:

  • Initiate therapy with 2 INVOKAMET® XR tablets, each tablet containing canagliflozin 50 mg and metformin 500 mg

In patients currently on metformin:

  • Switch to 2 INVOKAMET® XR tablets, where 2 tablets equal a starting dose of INVOKANA® 100 mg daily and the patient's current total daily dose (or nearest appropriate) of metformin

In patients currently on INVOKANA®:

  • Switch to 2 INVOKAMET® XR tablets, where 2 tablets equal the patient’s current total daily dose of INVOKANA® and a starting dose of metformin 1000 mg daily

In patients already treated with INVOKANA® and metformin:

  • Switch to 2 INVOKAMET® XR tablets containing the same total daily dose of INVOKANA® and the same, or nearest appropriate, total daily dose of metformin

Dosage and administration1

  • Take 2 INVOKAMET® XR tablets once daily with the morning meal
  • INVOKAMET® XR must be swallowed whole and never crushed, cut, or chewed
  • In patients who require additional glycemic control who are taking a total daily dose of INVOKANA® 100 mg, the INVOKAMET® XR dose can be increased to canagliflozin 300 mg once daily
  • The dose of metformin should be gradually escalated to reduce the gastrointestinal side effects due to metformin
  • Patients taking an evening dose of metformin XR should skip their last dose before starting INVOKAMET® XR the following morning
  • In patients with volume depletion not previously treated with INVOKANA®, correct this condition before initiating INVOKAMET® XR
  • Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin 2000 mg and canagliflozin 300 mg in patients with an eGFR ≥60 mL/min/1.73 m2
  • Assess renal function before initiating INVOKAMET® XR and periodically thereafter
  • INVOKAMET® XR is contraindicated in patients with an eGFR <45 mL/min/1.73 m2
  • Limit the dose of INVOKAMET® XR to 2 tablets, each tablet containing canagliflozin 50 mg, in patients with moderate renal impairment with an eGFR of 45 to <60 mL/min/1.73 m2

INVOKAMET® is available in 4 strengths2



The dosage of INVOKAMET® XR and INVOKAMET® should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose of canagliflozin (300 mg) and metformin (2000 mg).1,2

Individualize the starting dose of INVOKAMET® based on the patient's current regimen2

In patients currently not treated with either INVOKANA® or metformin:

  • Initiate therapy with INVOKAMET® containing canagliflozin 50 mg and metformin 500 mg

In patients currently on metformin:

  • Switch to INVOKAMET® containing canagliflozin 50 mg and the same, or nearest appropriate, daily dose of metformin

In patients currently on INVOKANA®:

  • Switch to INVOKAMET® containing metformin 500 mg with the same daily dose of canagliflozin

In patients already treated with INVOKANA® and metformin:

  • Switch to INVOKAMET® containing the same daily dose of INVOKANA® and the same, or nearest appropriate, daily dose of metformin

Dosage and administration2

  • Take 1 INVOKAMET® tablet twice daily with meals
  • In patients with volume depletion not previously treated with INVOKANA®, correct this condition before initiating INVOKAMET®
  • In patients tolerating canagliflozin 50 mg twice daily who have an eGFR ≥60 mL/min/1.73 m2 and require additional glycemic control, canagliflozin can be increased to 150 mg twice daily, with gradual metformin dose escalation to reduce the gastrointestinal side effects due to metformin
  • Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin 2000 mg and canagliflozin 300 mg in patients with an eGFR ≥60 mL/min/1.73 m2
  • Assess renal function before initiating INVOKAMET® and periodically thereafter
  • INVOKAMET® is contraindicated in patients with an eGFR <45 mL/min/1.73 m2
  • Limit the dose of the canagliflozin component to 50 mg twice daily in patients with moderate renal impairment with an eGFR of 45 to <60 mL/min/1.73 m2

SELECT IMPORTANT SAFETY INFORMATION

Adverse reactions: Canagliflozin and metformin

  • In 4 pooled 26-week placebo-controlled trials,* the most common (≥5%) adverse reactions associated with canagliflozin were2:
    • Female genital mycotic infection
    • Urinary tract infection
    • Increased urination
  • There were no additional adverse reactions identified when 3 of the placebo-controlled studies that included metformin were pooled separately, compared with the total 4 pooled placebo-controlled studies2
  • In a trial with canagliflozin as initial combination therapy with metformin, an increased incidence of diarrhea was observed in the canagliflozin and metformin combination groups (4.2%) compared to the canagliflozin or metformin monotherapy groups (1.3%, 1.7%, and 1.3%, respectively)3

*Included 1 monotherapy trial and 3 add-on combination trials with metformin, metformin + a sulfonylurea, or metformin + pioglitazone.

Learn about SAVINGS AND CAREPATH

References: 1. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. INVOKAMET® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Rosenstock J, Chuck L, González-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care. 2016;39(3):353-362.